Literature DB >> 19669356

Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies.

George Lau1, Patrick Marcellin, Marion Peters.   

Abstract

Chronic hepatitis B virus infection, a major cause of end-stage liver disease and hepatocellular carcinoma, is a worldwide health concern. While the past two decades have brought major advances in the availability of treatments to help delay or prevent these outcomes, treatment of chronic hepatitis B remains a serious challenge, not least due to the ability of the virus to remain in hepatocyte nuclei as a source of potential reactivation-hence the term chronic hepatitis B infection. This article reviews the current treatments available and suggests a framework for a rational approach to managing the disease.

Entities:  

Year:  2007        PMID: 19669356      PMCID: PMC2716826          DOI: 10.1007/s12072-007-9006-5

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  54 in total

1.  Chronic hepatitis B.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2007-02       Impact factor: 17.425

2.  Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.

Authors:  Yoon-Seon Lee; Dong Jin Suh; Young-Suk Lim; Suk Won Jung; Kang Mo Kim; Han Chu Lee; Young-Hwa Chung; Yung Sang Lee; Wangdon Yoo; Soo-Ok Kim
Journal:  Hepatology       Date:  2006-06       Impact factor: 17.425

Review 3.  Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease.

Authors:  R P Perrillo
Journal:  Gastroenterology       Date:  2001-03       Impact factor: 22.682

Review 4.  Clevudine for the treatment of chronic hepatitis B virus infection.

Authors:  Chee-Kin Hui; George K K Lau
Journal:  Expert Opin Investig Drugs       Date:  2005-10       Impact factor: 6.206

5.  Long-term remission of chronic hepatitis B after alpha-interferon therapy.

Authors:  J Korenman; B Baker; J Waggoner; J E Everhart; A M Di Bisceglie; J H Hoofnagle
Journal:  Ann Intern Med       Date:  1991-04-15       Impact factor: 25.391

6.  Entecavir resistance is rare in nucleoside naïve patients with hepatitis B.

Authors:  Richard J Colonno; Ronald Rose; Carl J Baldick; Steven Levine; Kevin Pokornowski; Cheng F Yu; Ann Walsh; Jie Fang; Mayla Hsu; Charles Mazzucco; Betsy Eggers; Sharon Zhang; Mary Plym; Kenneth Klesczewski; Daniel J Tenney
Journal:  Hepatology       Date:  2006-12       Impact factor: 17.425

Review 7.  A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update.

Authors:  Emmet B Keeffe; Douglas T Dieterich; Steven-Huy B Han; Ira M Jacobson; Paul Martin; Eugene R Schiff; Hillel Tobias; Teresa L Wright
Journal:  Clin Gastroenterol Hepatol       Date:  2006-07-14       Impact factor: 11.382

8.  Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis.

Authors:  D K Wong; A M Cheung; K O'Rourke; C D Naylor; A S Detsky; J Heathcote
Journal:  Ann Intern Med       Date:  1993-08-15       Impact factor: 25.391

9.  Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection.

Authors:  M van Zonneveld; A B van Nunen; H G M Niesters; R A de Man; S W Schalm; H L A Janssen
Journal:  J Viral Hepat       Date:  2003-07       Impact factor: 3.728

10.  Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B.

Authors:  G Fattovich; M Rugge; L Brollo; P Pontisso; F Noventa; M Guido; A Alberti; G Realdi
Journal:  Hepatology       Date:  1986 Mar-Apr       Impact factor: 17.425

View more
  4 in total

1.  Towards a rational treatment strategy for chronic hepatitis B.

Authors:  Yun-Fan Liaw
Journal:  Hepatol Int       Date:  2007-06-06       Impact factor: 6.047

2.  Are physicians following guidelines? A survey of Hepatitis B management strategies.

Authors:  Keat Hong Lee; Myat Oo Aung; Seng Gee Lim
Journal:  Hepatol Int       Date:  2012-10-06       Impact factor: 6.047

3.  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update.

Authors:  Yun-Fan Liaw; Nancy Leung; Jia-Horng Kao; Teerha Piratvisuth; Edward Gane; Kwang-Hyub Han; Richard Guan; George K K Lau; Stephen Locarnini
Journal:  Hepatol Int       Date:  2008-05-10       Impact factor: 6.047

4.  Less liver fibrosis marker increment in overweight chronic hepatitis B patients observed by age-adjusted Fibrosis-4 Index.

Authors:  Ta-Wei Liu; Chung-Feng Huang; Ming-Lun Yeh; Pei-Chien Tsai; Tyng-Yuan Jang; Jee-Fu Huang; Chia-Yen Dai; Wan-Long Chuang; Ming-Lung Yu
Journal:  BMJ Open Gastroenterol       Date:  2020-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.